RO7200220 for Diabetic Macular Edema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests vamikibart, an eye injection, in people with diabetic macular edema. The medication aims to reduce swelling and improve vision by being injected directly into the eye.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, certain treatments related to eye conditions, like anti-VEGF therapy, must be stopped for a specific period before starting the trial.
What safety data exists for RO7200220 (Ranibizumab, Lucentis, Susvimo, Vamikibart, RG-6179) in humans?
What data supports the effectiveness of the drug RO7200220 for Diabetic Macular Edema?
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for adults with diabetic macular edema, a condition causing swelling in the eye. Participants must have diabetes (Type 1 or Type 2), decreased vision due to DME, and agree to use effective contraception if applicable. They can't join if they've had certain treatments like anti-VEGF therapy recently, uncontrolled blood pressure, HbA1c >12%, are pregnant/breastfeeding, or have other eye conditions that affect vision.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravitreal injections of either vamikibart or ranibizumab, with varying dosages and frequencies, up to Week 44
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ranibizumab
- RO7200220
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University